A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 07 Nov 2023 Planned End Date changed from 30 Jun 2023 to 5 Nov 2024.
- 19 Apr 2023 Results (n=38, As of July 26, 2022) assessing the efficacy and safety of talimogene laherparepvec with pembrolizumab in patients with advanced melanoma, presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 04 Nov 2020 Status changed from recruiting to active, no longer recruiting.